Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric Cancer

Sponsor
Fujian Medical University
Study ID
NCT07314203
Phase
PHASE3
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Exploring the pathological complete response rate (pCR) of locally advanced gastric cancer treated with adebelimab combined or not combined with apatinib mesylate and SOX neoadjuvant therapy

Key Dates

Start date
Dec 25, 2026
Status verified
Dec 2025
Primary completion
Aug 25, 2027
Completion
Aug 25, 2028

Study Design

Enrollment
118 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: research group
    Study population received the combination of Adabelimab, Apatinib Mesylate, and SOX regimen

Primary Outcome Measure

Objective response rate [ Time Frame: 1 day ]

Central Contacts

Related Studies